Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. proteinplus

ProteinPlus SIGNED

Let's give the world appetite for health

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ProteinPlus project word cloud

Explore the words cloud of the ProteinPlus project. It provides you a very rough idea of what is the project "ProteinPlus" about.

half    designed    nutricia    reducing    copy    invented    dominated    capital    170bn    proving    limiting    founded    bad    formulated    abbott    taste    savings    barrier    portion    healthcare    120    emulsion    disease    manufacture    standards    emulsar    prepare    50    manufacturers    medical    million    eacute    disruptive    industrial    nestl    full    deficiencies    clinical    density    create    patented    33    2012    public    sizes    reduce    malnutrition    technological    transition    plus    levels    casino    employees    dramatically    proof    foods    nutritional    patients    smart    validate    generating    mass    ons    tastier    optimize    nice    sustainability    food    prevents    launch    tons    competitiveness    compliance    compatibility    health    supplements    leader    treatment    meet    ingredients    fresenius    proved    protein    nutrition    volumes    2004    burden    2020    volume    revenues    10bn    sent    dense    nanotechnology    75m    unilever    commercial    overcomes    effectiveness    reaching    market    lab    hundreds    oral    specially    ingredient    proteins    illness    healthier    induce    europeans    gap    hyperproteinic   

Project "ProteinPlus" data sheet

The following table provides information about the project.

Coordinator		 EMULSAR 

Organization address
address: 26-28 rue Marius Aufan
city: Levallois-Perret
postcode: 92300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website http://www.emulsar.com/
 Total cost 2˙449˙800 €
 EC max contribution 1˙714˙860 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2020-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EMULSAR FR (Levallois-Perret) coordinator 1˙714˙860.00

Map

 Project objective

Disease-related malnutrition affects 33 million Europeans, a burden of 170bn€ for the EU. Oral Nutritional Supplements (ONS) are specially formulated foods designed to meet patients’ nutritional deficiencies during illness. This $10Bn ONS market is dominated by Nutricia, Nestlé, Fresenius & Abbott.

However, large portion sizes and bad taste in ONS induce very low levels of treatment compliance (50%), dramatically limiting effectiveness. Manufacturers face a technological barrier that prevents them from increasing protein density and thus reducing volume.

The aim of the project is to bring to the market a disruptive hyperproteinic ingredient – Protein Plus© - for ONS manufacturers, that overcomes this technology gap.

Founded in 2004, EMULSAR invented and patented its Smart Emulsion Nanotechnology© (SENT©), used to manufacture disruptive ingredients for health and nutrition. Since 2012, SENT© has produced hundreds of tons of food ingredients (used by Casino, Unilever…to create healthier & tastier products), proving its industrial sustainability and compatibility with commercial food standards.

In Phase 1, we proved (at lab-scale) that by applying SENT© to proteins, we can produce a protein-dense ingredient that makes it possible to reduce current ONS volumes by half.

Our Phase 2 objectives are to optimize our Protein Plus© ingredient, validate the industrial process, establish clinical proof of improved ONS compliance & prepare our market launch.

Our project will improve the competitiveness of ONS products, create public healthcare savings and enhance Europe’s health capital. For EMULSAR, the ONS market is the best path for becoming a European technology leader in health food, allowing EMULSAR to transition from nice-to-have applications (mass-market food) to must-have applications (medical nutrition). The current project is the key to reaching the full commercial potential of our nanotechnology, generating 75M€ in revenues & managing 120 employees by 2020.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROTEINPLUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROTEINPLUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

SHN (2017)

Universal Smart Hypodermic Needle for preventing reuse and accidental pricks

Read More  

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

SUPPLEPRINT (2018)

Super Productive Line Printing Inkjet

Read More